The Department of Veterans Affairs (VA) awarded a firm fixed price, indefinite delivery/indefinite quantity (IDIQ) contract to Cepheid, a for-profit manufacturer of molecular diagnostic solutions, for the provision of GeneXpert reagents. The contract, valued at $82,233.75, will support various molecular tests on VA patients including MRSA, CDIFF, STD, and screening for genetic mutations and flu. The contract does not have a set-aside designation. Cepheid has a history of supplying the VA with molecular reagents, test kits, and GeneXpert diagnostic systems to support the agency's clinical testing programs. This contract award is part of the VA's ongoing procurement of Cepheid's molecular diagnostic solutions to serve veteran healthcare needs.